The best of the 2019 American College of Cardiology Congress

Abstract

As every year, on this occasion the 68th Congress of the American College of Cardiology was held from March 16 to 18 in New Orleans, Louisiana. Set in the city of Mardi Gras and jazz, it once again called on global cardiology to promote knowledge through the presentation of multiple scientific activities. It counted with the presence of more than 16.000 attendees and 2.300 articles were received, many of which will undoubtedly modify the current clinical practice. It is also worth mentioning the presentation of the Primary Prevention of Cardiovascular Disease Guideline, which highlights the almost total discontinuation of acetylsalicylic acid in primary prevention due to the lack of net benefit.
We will make a brief summary of some of the main scientific papers presented:

• Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation – The AUGUSTUS Trial
• TranscatheterAortic-ValveReplacement with aBalloon-ExpandableValve in Low-Risk Patients –ThePARTNER3 trial
• The Safety and Efficacy of Femoral Access in STEMI: The SAFARI-STEMI Trial
• One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial
• Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch: The Apple Heart Study